Alliance Global Partners Maintains Buy on Icecure Medical, Raises Price Target to $2.9
Portfolio Pulse from Benzinga Newsdesk
Alliance Global Partners analyst Ben Haynor has maintained a Buy rating on Icecure Medical (NASDAQ:ICCM) and increased the price target from $1.9 to $2.9. This adjustment reflects a positive outlook on the company's future performance.
March 20, 2024 | 4:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Icecure Medical's Buy rating is maintained by Alliance Global Partners, with the price target increased from $1.9 to $2.9, indicating a positive future outlook.
The increase in price target by a reputable analyst suggests a strong confidence in Icecure Medical's future performance. This is likely to positively influence investor sentiment and potentially lead to an increase in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100